Keyphrases
Follicular Lymphoma
100%
Rituximab Maintenance
100%
Improved Outcomes
100%
Histological Transformation
80%
Induction Treatment
40%
Progression-free Survival
40%
Training Population
40%
5-year Survival
40%
Rituximab
40%
Risk Reduction
20%
Time-related
20%
Chemotherapy
20%
Maintenance Treatment
20%
Anti-CD20 Antibody
20%
Lymphoma Patients
20%
Prognostic Score
20%
Validation Cohort
20%
Bone Marrow Infiltration
20%
Present Population
20%
Population-based Cohort
20%
Population Data
20%
International Prognostic Index
20%
Medicine and Dentistry
Follicular Lymphoma
100%
Rituximab
100%
Chemotherapy
50%
Overall Survival
50%
Progression Free Survival
50%
Maintenance Therapy
25%
Clinical Stage
25%
CD20 Antibody
25%
Hope
25%